# Oxitope Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oxitope-pharma-b-v

- Industry: Biotechnology
- Headquarters: Naarden, Netherlands
- Website: www.oxitopepharma.com/
- Latest round: Seed (Sep 16, 2021)
- Investors on record: 1

## About

Founded in 2020 and based in the Netherlands, Oxitope Pharma B.V. is a biopharmaceutical start-up that engages in the discovery and development of medicines for the treatment of inflammatory and cardiovascular diseases caused by oxidative stress. In January 2024, Oxitope Pharma B.V. merged with Arxx Therapeutics AS, a portfolio company of Rasmussengruppen AS, Investinor, altitude Capital Management, Veen Eiendom AS, P53, Sarsia Management, Trond Mohn Stiftelsen, MP Pensjon, Asteroidebakken AS, and Andenes Investments, to form Calluna Pharma. As of 2024, the company is led by its CEO, John Montona.

The company focuses on developing drugs to treat inflammatory and cardiovascular disorders caused by oxidised phospholipids. The firm's strategy is based on avoiding, slowing, or even reversing acute and chronic diseases. Oxitope specializes in the identification and development of oxidised phospholipid (OxPL) antibodies, with a focus on their therapeutic potential across a wide range of disorders involving inflammation and cellular signalling networks.

Oxidized phospholipids (OxPLs) are complex molecules produced during normal or pathological processes. The company's first development candidate focuses on acute indications, particularly cardiovascular disease (CVD). Oxitope Pharma has identified OxPLs in MI-IRI and their association with elevated cardiovascular disease risk. The company is also working on antibodies that target oxidation-specific epitopes (OSEs) on OxPLs.

## Funding rounds

- Seed, Sep 16, 2021 — Forbion

## Investors

- Forbion (https://capitalatlas.ai/funds/forbion) — Seed